WHO ICTRP trial
Safety and preliminary efficacy of JK500 cell injection in relapsed/refractory…
ChiCTR2200062539 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200062539 |
|---|---|
| Public title | Safety and preliminary efficacy of JK500 cell injection in relapsed/refractory pediatric acute myeloid leukemia |
| Scientific title | Safety and preliminary efficacy of JK500 cell injection in relapsed/refractory pediatric acute myeloid leukemia |
| Primary sponsor | Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 1 |
| Countries | China |
| Conditions | relapsed/refractory pediatric acute myeloid leukemia |
| Interventions | The treatment group:JK500 cell injection |
| Registration date | Aug 11, 2022 |
| Target size | The treatment group:12 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: